Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms.

Authors: David J. Casarett, Jessica N. Beliveau, and Michelle S. Arbus
Journal of Palliative Medicine, 6 August 2019

Objectives: To determine the relative contributions of tetrahydrocannabinol (THC) and cannabidiol (CBD) to patients’ self-ratings of efficacy for common palliative care symptoms. Design: This is an electronic record-based retrospective cohort study. Model development used logi…

Use and effects of cannabinoids in military veterans with posttraumatic stress disorder.

Authors: Kevin Betthauser, Jeffrey Pilz, Laura E. Vollmer
American Journal of Health-System Pharmacy, 1 August 2015

PURPOSE: Published evidence regarding the use of cannabis and cannabis derivatives by military veterans with posttraumatic stress disorder (PTSD) is reviewed. SUMMARY: When inhaled or delivered orally or transdermally, cannabinoids (the psychoactive components of unrefined mar…

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Authors: John Peter Zajicek, Jeremy C. Hobart, Anita Slade, David Barnes, Paul G. Mattison
Journal of Neurology, Neurosurgery, & Psychiatry, November 2012

OBJECTIVE: Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of pr…

Hypnotic and antiepileptic effects of cannabidiol.

Authors: Elisaldo A. Carlini, Jomar M. Cunha
The Journal of Clinical Pharmacology, August-September 1981

Clinical trials with cannabidiol (CBD) in healthy volunteers, isomniacs, and epileptic patients conducted in the authors’ laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days o…